UBS: First coverage of British Silicon Intelligence (03696) with a "Buy" rating, target price of HK$77.

According to the Zhixingtong Finance and Economics app, UBS has released a research report stating that it is initiating coverage of British Silicon Intelligence (03696) with a "buy" rating and a target price of 77 Hong Kong dollars, which is equivalent to a predicted market sales ratio of 31.3 times for this year, in line with global peers. The bank pointed out that British Silicon Intelligence is a global leader in AI-driven drug discovery (AIDD) companies, using its end-to-end proprietary Pharma.AI platform for drug discovery and pipeline development, with this business accounting for 87% of total revenue in 2025.